厄洛替尼对EGFR外显子19与21突变晚期非小细胞肺癌患者的疗效比较(4)
[ 7 ] SAKATA Y，KAWAMURA K，SHINGU N，et al. Erloti- nib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer[J]. Lung Cancer，2016.DOI：10.1016/j.lungcan.2016.07.008.
[ 8 ] FURUGAKI K，FUKUMURA J，IWAI T，et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification[J]. Inter J Cancer，2016，138(4)：1024-1032.
, http://www.100md.com
[ 9 ] EISENHAUER EA，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline(version 1.1)[J]. Eur J Cancer，2009，45(2)：228-247.
[10] U S Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0[M]. Bethesda：National Institutes of Health，National Cancer Institute，2009：3-179.
[11] ROSELL R，CARCERENY E，GERVAIS R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non- small-cell lung cancer (EURTAC)：a multicentre，open-label，randomised phase 3 trial[J]. Lancet Oncol，2012，13(3)：239-246.
, http://www.100md.com
[12] SIEGEL RL，MILLER KD，FEDEWA SA，et al. Colorectal cancer statistics，2017[J]. CA Cancer J Clin，2017，67(3)：177-193.
[13] GARNETT MJ，EDELMAN EJ，HEIDORN SJ，et al. Systematic identification of genomic markers of drug sensitivity in cancer cells[J]. Nature，2012，483(7391)：570-575.
[14] ROLFF J，BECKER M，MERK J，et al. Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts[J]. Targeted Oncology，2016，90(4)：1-8.
, http://www.100md.com
[15] 石遠凯，孙燕，于金明，等.中国晚期原发性肺癌诊治专家共识：2016年版[J].中国肺癌杂志，2016，19(1)：1-15.
[16] WANG H，HUANG J，YU X，et al. Different eficacy of EGFR tymsine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer：a meta analysis[J]. J Cancer Res Clin Oncol，2014，140(11)：1901-1909.
[17] 冯佳，许斌，宋启斌. EGFR19与21号外显子突变的晚期非小细胞肺癌一线TKI治疗疗效差异的研究进展[J].肿瘤学杂志，2016，22(3)：167-171.
[18] GRIDELLI C，BALDUCCI L，CIARDIELLO F，et al. Treatment of elderly patients with non-small cell lung cancer：results of an international expert panel meeting of the italian association of thoracic oncology[J]. Clin Lung Cancer，2015，16(5)：325-333.
(收稿日期：2017-06-02 修回日期：2017-08-22)
(编辑：邹丽娟), 百拇医药(翁克贵 郭兵 候彦华 蒋勇 王颖 王渝东)
[ 8 ] FURUGAKI K，FUKUMURA J，IWAI T，et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification[J]. Inter J Cancer，2016，138(4)：1024-1032.
, http://www.100md.com
[ 9 ] EISENHAUER EA，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline(version 1.1)[J]. Eur J Cancer，2009，45(2)：228-247.
[10] U S Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0[M]. Bethesda：National Institutes of Health，National Cancer Institute，2009：3-179.
[11] ROSELL R，CARCERENY E，GERVAIS R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non- small-cell lung cancer (EURTAC)：a multicentre，open-label，randomised phase 3 trial[J]. Lancet Oncol，2012，13(3)：239-246.
, http://www.100md.com
[12] SIEGEL RL，MILLER KD，FEDEWA SA，et al. Colorectal cancer statistics，2017[J]. CA Cancer J Clin，2017，67(3)：177-193.
[13] GARNETT MJ，EDELMAN EJ，HEIDORN SJ，et al. Systematic identification of genomic markers of drug sensitivity in cancer cells[J]. Nature，2012，483(7391)：570-575.
[14] ROLFF J，BECKER M，MERK J，et al. Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts[J]. Targeted Oncology，2016，90(4)：1-8.
, http://www.100md.com
[15] 石遠凯，孙燕，于金明，等.中国晚期原发性肺癌诊治专家共识：2016年版[J].中国肺癌杂志，2016，19(1)：1-15.
[16] WANG H，HUANG J，YU X，et al. Different eficacy of EGFR tymsine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer：a meta analysis[J]. J Cancer Res Clin Oncol，2014，140(11)：1901-1909.
[17] 冯佳，许斌，宋启斌. EGFR19与21号外显子突变的晚期非小细胞肺癌一线TKI治疗疗效差异的研究进展[J].肿瘤学杂志，2016，22(3)：167-171.
[18] GRIDELLI C，BALDUCCI L，CIARDIELLO F，et al. Treatment of elderly patients with non-small cell lung cancer：results of an international expert panel meeting of the italian association of thoracic oncology[J]. Clin Lung Cancer，2015，16(5)：325-333.
(收稿日期：2017-06-02 修回日期：2017-08-22)
(编辑：邹丽娟), 百拇医药(翁克贵 郭兵 候彦华 蒋勇 王颖 王渝东)